Practical guidance for the management of side effects during rucaparib therapy in a multidisciplinary UK setting

Therapeutic Advances in Medical Oncology
Laura TookmanIain A McNeish

Abstract

The use of targeted therapeutics known as poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors in the management of ovarian cancer is currently transforming clinical practice. The PARP inhibitor rucaparib is indicated in the UK, European Union and the United States for use in the treatment and maintenance settings for patients with relapsed ovarian cancer. Here, we discuss some of the real-world challenges and side effects that we have encountered while prescribing rucaparib, and we provide practical guidance on how the individual members of our multidisciplinary team (MDT), including a clinician, chemotherapy nurse practitioner, and clinical pharmacist, collaborate to manage these side effects. If recognized early, the side effects experienced by patients during rucaparib therapy, which include fatigue, nausea and vomiting, liver enzyme elevations, and anemia, can be easily managed. For example, providing patients with prophylactic antiemetics can help them avoid nausea, and early detection of decreases in hemoglobin levels allows for proactive interventions to alleviate anemia. The MDT should work together with the patient to identify potential side effects early and manage them effectively. The aim of this proacti...Continue Reading

References

Mar 17, 2007·Molecular Cancer Therapeutics·Huw D ThomasNicola J Curtin
Jul 2, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Alan Ashworth
Jul 2, 2011·Nature·UNKNOWN Cancer Genome Atlas Research Network
Feb 22, 2012·Nature Biotechnology·Elisabet WahlbergJohan Weigelt
Mar 29, 2012·The New England Journal of Medicine·Jonathan LedermannUrsula Matulonis
Aug 23, 2012·Annals of Oncology : Official Journal of the European Society for Medical Oncology·L C HankerUNKNOWN AGO and GINECO study group
Oct 23, 2013·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J A LedermannUNKNOWN ESMO Guidelines Working Group
Nov 19, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Kathryn P PenningtonElizabeth M Swisher
Jan 9, 2015·Cancer Metastasis Reviews·Maurie Markman
Sep 30, 2016·Xenobiotica; the Fate of Foreign Compounds in Biological Systems·Alex McCormick, Helen Swaisland
Oct 9, 2016·The New England Journal of Medicine·Mansoor R MirzaUNKNOWN ENGOT-OV16/NOVA Investigators
Aug 11, 2017·Therapeutic Advances in Medical Oncology·Robert T NeffRitu Salani
Nov 18, 2017·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M Aapro
Nov 29, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Charles A SchifferKenneth C Anderson
Jul 18, 2018·Annals of Oncology : Official Journal of the European Society for Medical Oncology·P J LarkinUNKNOWN ESMO Guidelines Committee
Oct 23, 2018·The New England Journal of Medicine·Kathleen MoorePaul DiSilvestro
Jan 8, 2019·The Lancet Oncology·Christopher J LaFargueRobert L Coleman
May 3, 2019·Annals of Oncology : Official Journal of the European Society for Medical Oncology·N ColomboUNKNOWN ESMO-ESGO Ovarian Cancer Consensus Conference Working Group
Aug 14, 2019·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Sara BouberhanStephen A Cannistra
Sep 29, 2019·The New England Journal of Medicine·Antonio González-MartínUNKNOWN PRIMA/ENGOT-OV26/GOG-3012 Investigators
Sep 29, 2019·The New England Journal of Medicine·Robert L ColemanMichael A Bookman
Nov 7, 2019·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·Rebecca S KristeleitIain A McNeish
Dec 4, 2019·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·Graziela Zibetti Dal MolinRobert L Coleman
Jan 29, 2020·Annals of Oncology : Official Journal of the European Society for Medical Oncology·N ColomboUNKNOWN ESMO-ESGO Ovarian Cancer Consensus Conference Working Group
Oct 1, 2018·Annals of Oncology : Official Journal of the European Society for Medical Oncology·P J LarkinUNKNOWN ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org

❮ Previous
Next ❯

Clinical Trials Mentioned

NCT01482715
NCT01891344

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.